New predictors of cardiovascular events are needed to improve the accuracy of risk stratification. Such predictors should be easily measurable in the population and potentially modifiable. This review reports on new biomarkers that are closely linked to the pathogenic mechanisms underlying the progression of the atherosclerotic plaque leading to rupture and thrombosis that ultimately precipitate acute clinical events, such as stroke and myocardial infarction. These risk factors have been associated with subclinical or clinical cardiovascular disease in large populations and include markers of lipoprotein and lipid metabolism, vitamin B12 metabolism, fibrinolysis, coagulation, inflammation, infection, endothelial dysfunction, the angiotensin system, and oxidative stress. For other key processes of atherosclerosis and cardiac disease, such as apoptosis or programmed cell death, there are currently no markers that can be measured noninvasively. Atherosclerosis is a multifactorial condition and possibly only a subset of factors are the main determinants of disease in a given patient. A better definition of the cardiovascular risk profile will help to better target primary and secondary prevention. Further epidemiological studies are needed to characterize the actual predictive and clinical value of these new emerging cardiovascular biomarkers.
In the United States the age-adjusted rates of cardiovascular mortality have declined by more than 50% in the last quarter century among whites and blacks of both sexes. This achievement is in part a shared success of both improved treatment and effective primary prevention. Current disease prevention strategies focus on reducing blood lipids (particularly low-density lipoprotein [LDL]), blood pressure control, serum glucose control, weight control, increasing physical activity, and smoking cessation. As currently implemented, these strategies may have reached the limits of their effectiveness. During the past few years the decline from coronary disease death has tended to level and the death rates from stroke have slightly increased.1 As important as the established risk factors are for predicting disease, only a fraction of those who have 1 or more of these risk factors will actually develop a cardiovascular event, and some with no known risk factors will experience an event. There is, however, cause for optimism. Important advances in our understanding of the pathogenesis of disease and in the genetics that mediate the relationship between risk factors and disease have opened large new areas for epidemiological exploration. This article provides a brief overview of emerging biomarkers of atherosclerosis that are suitable for evaluation in prospective epidemiological studies. As they are evaluated, we should be better able to identify individuals at risk of clinical cardiovascular events and new targets for intervention.
The transition from subclinical cardiovascular disease to overt clinical disease is usually precipitated by acute coronary events such as unstable angina or myocardial infarction. Pathologic evidence indicates that rupture, erosion, and fissure of lipid-rich vulnerable atherosclerotic plaques are probably the most frequent underlying mechanisms that trigger the cascade of effects leading to acute coronary occlusion.2 Current hypotheses concerning the pathogenesis of this cascade focus on endothelial injury, the oxidation of LDPs and their effects on the endothelium, the interaction of growth factors and cytokines leading to increased oxidative stress, increased free radical formation, destruction of nitric oxide, endothelial dysfunction, increased platelet aggregation, inflammation, proteolysis, impaired thrombolysis, and thrombosis. Although there are no sensitive and practical means of detecting vulnerable plaques in the coronary arteries in vivo, several serologic markers associated with each of the pathophysiological processes leading to plaque rupture and fissure, and thrombosis might help to identify those individuals with subclinical disease who will most likely experience a new coronary event. Recently identified biomarkers including markers of lipoprotein metabolism, endothelial dysfunction, fibrinolysis, and inflammation have been associated with an excess risk of subclinical or clinical cardiovascular disease, and have been linked with key atherogenic or prothrombotic mechanisms. These biomarkers may better predict clinical events either alone or in combination with traditional established cardiovascular risk factors. However, the independent relation of these new risk factors with atherosclerotic disease has not yet been conclusively proven.
Specific lipoprotein and fatty acid metabolism markers are linked with the formation of lipid-rich plaques and thrombosis. Lipoprotein(a) [Lp(a)] can promote atherosclerotic disease by increasing deposition of cholesterol into the arterial wall, enhancing oxidation of LDL cholesterol, and interfering with fibrinolysis. Lipoprotein(a) is emerging as one promising target for intervention such as niacin.3 In the Framingham studies and in another large cohort Lp(a) was found to be a powerful independent predictor of coronary disease,4-6 and in Atherosclerosis Risk in Communities study Lp(a) was independently associated with cerebrovascular disease and asymptomatic atherosclerosis.7,8 Genetic factors affect Lp(a) levels that vary substantially according to sex and race.9 For example, the distribution of Lp(a) in white Americans and Asian Indians are more skewed to the left, while this distribution is nearly normal in African Americans.10
Cholesteryl ester transfer protein (CETP), lipoprotein lipase (LPL), and hepatic lipase are major determinants of the plasma high-density lipoprotein (HDL) cholesterol and triglyceride levels, and play an important role in the reverse cholesterol transport system. Although the relationship between the actions of these proteins and atherosclerosis is complex and not fully documented, a body of evidence suggests that polymorphisms of the CETP, LPL, and hepatic lipase genes influence the levels of these lipoproteins and may be independent predictors of atherosclerotic risk.11-15 Furthermore, these polymorphisms are relatively frequent in the population and may be more suitable measures in epidemiological studies.14,16,17 These genetic polymorphisms are particularly relevant because of racial differences in their distribution—for example, CETP mutations are frequent among individuals of Japanese ancestry—and their interaction with environmental factors such as diet, smoking, alcohol intake, and medication use.11-13,16-20 Emerging evidence suggests that HDL cholesterol subfractions may be independent risk factors of atherosclerotic disease. In the Cardiovascular Health Study (CHS) HDL2-C and HDL3-C were decreased in individuals with prevalent cardiovascular disease, and HDL3-C was correlated with carotid atherosclerosis.21 In another study,22 there was a strong association of HDL2 (inverse) and CETP (direct) with carotid intimal media thickness. The strongest predictor of intimal media thickness was the CETP content of the dense HDL3 subfraction expressed as the ratio of CETP/HDL3.22
Triglyceride-rich lipoproteins such as intermediate-density lipoproteins and very low-density lipoprotein or chylomicron remnants are emerging as predictors of atherosclerosis. They are involved in the pathogenesis of atherosclerosis either directly as atherogenic particles,23 or indirectly by altering the composition of other lipoproteins such as LDL and HDL. There is a strong and consistent association of hypertriglyceridemia with dense LDL.24,25 Decreased LDL particle size has in turn been associated with premature coronary artery disease,24,25 and intermediate-density lipoproteins have been independently associated with the progression of carotid26 and coronary atherosclerosis.27 Additional relevant lipid markers include fasting and peak postprandial triglyceride and remnant lipoprotein,28,29 plasma fatty acid composition (phospholipid and cholesterol ester),30 total plasma apoA1 and apoB, and common apo(a) (kringle type 2), apoB, apoE gene polymorphisms (E2/E4).7,31-35 The recent development of a rapid method for separating very low-density lipoprotein and chylomicron remnant particles from whole plasma offers a new tool for studying the relationship of remnant particles with atherosclerotic disease.36 This method isolates apoB48 and apoB100 particles that are enriched in apoE and cholesteryl ester and/or depleted in C apoproteins, characteristics of remnant particles of chylomicron and very low-density lipoprotein, respectively. In limited studies to date, elevated levels of these remnant lipoproteins have been observed in subjects with coronary artery disease and in diabetes mellitus.37
Studies of the red blood cell membrane fatty acid and lipid composition can gather important information on the antioxidant defenses.38,39 Changes in red blood cell membrane fatty acid and lipid composition reflect dietary fat intake,40 and are associated with modifications in sodium-lithium countertransport,41 an independent predictor of onset of hypertension in normotensive individuals.42
Homocysteine can promote vascular disease by means of direct cytotoxic effects on the endothelium, increased adhesiveness of the platelets, and effects on clotting factors.43 Elevated levels of homocysteine have been linked with increased risk of carotid stenosis,44 vascular disease,45 myocardial infarction in young women,46 venous thromboembolism,47 and mortality among patients with coronary disease.48 Levels of homocysteine vary according to age, sex, race, and genotype and environmental factors such as diet and medication use.43 Polymorphisms of the thermolabile methylenetetrahydrofolate reductase, the key enzymes of homocysteine metabolism, are associated with increased levels of homocysteine and excess cardiovascular risk.46,49
Fasting plasma levels of plasma homocysteine in a normal population generally range from 5 to 15 µmol/L.50 Even mild elevations (>10-15 µmol/L) are associated with increased risk of atherosclerotic vascular disease, and a homocysteine level in excess of 16 µmol/L is associated with a 3-fold increase in risk of coronary heart disease.51 Elevated plasma homocysteine may arise from both nutritional and genetic factors. Plasma levels of homocysteine are higher in individuals whose plasma levels of vitamins B12, B6 (pyridoxine), B9 (folate), and pyridoxal phosphate are in the bottom quartile and substantial health benefits are expected from an increase in dietary folate.51 Plasma homocysteine increases with age, postmenopausal state, renal disease, and with administration of diphenylhydantoin and carbamazepine.43
Thrombosis and hemostasis
Alterations in thrombosis and hemostasis are causally linked to atherosclerotic disease and can precipitate acute events. Markers, such as increased levels of fibrinogen, fibrinogen β mutation,31,52 plasmin-α-antiplasmin complex, plasminogen activator inhibitor 1 (PAI-1), tissue-type plasminogen activator antigen (TPA), and D-dimer can identify high-risk individuals.53-60 Some of these markers, such as PAI-1 activity or antigen, are indicators of inhibited fibrinolysis, others, such as TPA antigen, D-dimer, and plasmin-α-antiplasmin complex, are indicators of the activation of the fibrinolytic system. In CHS increased levels of plasmin-α-antiplasmin complex independently predicted myocardial infarction and coronary death.61 In the Atherosclerosis Risk in Communities Study, participants with subclinical atherosclerosis had significantly increased levels of PAI-1, TPA, and D-dimer, compared with those with no atherosclerotic disease.54 Increased PAI-1 is likely one mechanistic link between glucose intolerance or diabetes with increased risk of atherothrombotic events.55 In prospective studies56-58 PAI-1 and TPA independently predicted cardiovascular events or mortality. The PAI-1 activity or antigen seem to be better predictors of events than the known polymorphisms that regulate PAI-1(4G/5G mutation).31,62 Gene polymorphism of the TPA seems to be a better predictor of myocardial infarction than TPA activity or antigen.63 Fibrinolytic markers are affected by medication use and diet.64-66 While some studies57,67 found that the significant associations of TPA with cardiovascular disease were independent of other risk factors, others55,60,63,68,69 have found that fibrinolytic markers were correlated with insulin resistance, obesity, and serum lipids such as total cholesterol and Lp(a), suggesting that the prothrombotic effect of altered lipids and diabetes are mediated by an impairment of fibrinolysis.
Angiotensin and cellular calcium play an important role in regulating the production of PAI-1,70-72 and antihypertensive agents, such as angiotensin-converting enzyme (ACE) inhibitors and calcium channel blockers, may have beneficial effects on fibrinolysis. In 1 study65 120 patients were randomized to ramipril or placebo 24 hours after an acute myocardial infarction to assess the effects on fibrinolytic markers. After 2 weeks PAI-1 antigen and activity were significantly decreased in the ramipril group compared with the placebo group by 44% and 22%, respectively. In a smaller trial73 of 81 patients enrolled after an acute myocardial infarction, those randomized to enalapril had significantly lower levels of TPA antigen compared with placebo, but no difference was found in PAI-1 after 12 weeks of treatment, although baseline levels of PAI-1 and TPA were unknown and blood samples were not optimally stored. Another small study74 in 12 patients with coronary heart disease, obesity, and hypertension failed to find any significant effect of lisinopril on TPA or PAI-1 antigen after 12 weeks of treatment. The use of captopril significantly reduced the levels of PAI-1 and TPA in 14 patients with postmyocardial infarction but not in placebo-treated controls.75 In a trial56 that compared verapamil with metoprolol in 809 patients with stable angina, 631 patients were evaluated for fibrinolytic markers. The TPA antigen and PAI-1 activity, but not the type of treatment, predicted coronary events. Compared with baseline values, the use of verapamil and metoprolol were associated with a 10% decrease and a 2% increase in TPA, respectively (P<.001 for treatment difference, P was not significant for the variation vs baseline).
Other relevant hemostatic factors that predict coronary events or that are associated with atherosclerosis include increased levels of factor VII,76 factor VII polymorphisms vary with race and are associated with an increased risk of myocardial infarction,77,78 factor VIII, thromboplastin, von Willebrand factor,59 thromboglobulin,79 and markers of platelet activation, such as prothrombin fragment 1+2,80,81 and in young women factor Leiden V mutation.82 The frequency of factor V Leiden varies depending on geographic locations and ethnic diversity. In CHS mutations of the factor V gene that were particularly frequent among blacks, were significantly associated with intimal media thickness and prevalent cardiovascular disease.83
Inflammation and infectious agents
Inflammation may be both important in the pathogenesis of atherothrombosis and a distal marker of an advancing disease process. Increases in the serum C-reactive protein prospectively predict coronary events.84-87 The protective effect of aspirin on coronary events may be in part mediated by the anti-inflammatory properties of the drug,84 suggesting that the association between inflammation and coronary disease is likely causal. In experimental studies88 increases in interleukin 6 (IL-6) and tumor necrosis factor α cause coronary arteriosclerosislike changes in the smooth muscle. Increased serum levels of IL-6 and tumor necrosis factor α are associated with severity of left ventricular dysfunction89 and are candidates for predicting atherosclerotic disease. It is well established that IL-6 levels are increased in heart failure and in specific inflammatory diseases. Increased levels of circulating transforming growth factor β1 are associated with both diabetes and coronary disease.90,91 Emerging evidence is showing that in the general population IL-6 levels are correlated with several chronic conditions. In a community sample of men from the general population in the United Kingdom plasma IL-6 levels were significantly correlated with smoking, chronic pulmonary disease, high triglyceride levels, high fibrinogen, and coronary disease.92 In a small sample of postmenopausal women plasma IL-6 was negatively correlated with serum estradiol and bone density.93 In a large population sample of the Established Populations for Epidemiologic Studies of the Elderly, IL-6 levels were correlated with functional disability, cancer, heart disease, and hypertension.94 Polymorphisms of the transforming growth factor β1 and tumor necrosis factor α genes have been associated with severity of atherosclerosis and hypertension or diabetes.95,96 Frequent IL-6 polymorphisms modulate IL-6 levels.97
Infectious agents, such as Chlamydia, cytomegalovirus, Helicobacter pylori, and herpes simplex virus, have been associated with an excess risk of coronary disease.98-102 These pathogens have been implicated in the pathogenesis of atherosclerosis by in vitro studies in which infection of smooth muscle cells with these agents (herpes simplex virus I and II) produces changes similar to those observed in the atherosclerotic plaque, by detection of viral and bacterial antigens and genetic material in human atherosclerotic lesions (Chlamydia, H pylori, cytomegalovirus, and herpes simplex virus 2)102 and by seroepidemiological studies.103 The presence of seropositivity for cytomegalovirus and the titer of anticytomegalovirus IgG antibodies were powerful and independent predictors of coronary restenosis after directional atherectomy.101
The evidence of a role of Hpylori in the pathogenesis of atherosclerosis is less clear.99,104 Although 1 cross-sectional study99 reported a higher prevalence of seropositivity for H pylori in patients with vs those without coronary heart disease (76.6% vs 45.5%, respectively), another prospective cross-sectional study104 found no evidence of increased titers to H pylori among 342 patients admitted with myocardial infarction. In 1 cross-sectional study,105 22% of patients with coronary heart disease had high (>1:64) antibody titers against Chlamydia pneumoniae vs 4.7% of healthy controls. It remains debated whether these infectious agents have a causal effect on atherothrombosis or are merely an epiphenomenon of the inflammatory process.
Increased levels of biochemical markers of endothelial function and cell adhesion—P-selectin, E-selectin, soluble intercellular adhesion molecule 1, vascular cell adhesion molecule 1, and thrombomodulin—have been found in patients with atherosclerosis and dyslipidemia.106-110 Increased circulating levels of E-selectin, soluble intercellular adhesion molecule 1, vascular cell adhesion molecule 1, and thrombomodulin have been found in patients with atherosclerosis and dyslipidemia.106-110 In the Atherosclerosis Risk in Communities Study, increased plasma levels of intercellular adhesion molecule 1 and E-selectin prospectively predicted coronary events.111 In the Physician's Health Study, intercellular adhesion molecule 1 was significantly and independently associated with incident myocardial infarction.112 DNA polymorphisms of adhesion molecule genes have been identified in young subjects with angiographically documented coronary atherosclerosis.113,114 Endothelin is an endothelial-derived vasoconstrictor peptide with mitogenic properties that has been associated with severity of coronary disease.115 Apoptosis, or programmed cell death, is an important mechanism underlying the atherothrombotic process, myocardial ischemia, and heart failure, but, currently there are no noninvasive measures of apoptosis.116-118
Angiotensin plays a pivotal role in vascular remodeling, and regulation of vasoconstriction and thrombolysis. The insertion and deletion polymorphisms of the ACE gene account for up to 50% of interindividual variability in ACE levels.31 Although genotyping is a more reliable marker of tissue levels of ACE than ACE serum levels, the findings on the associations of ACE polymorphisms with coronary disease have been contradictory.119,120 Racial differences may have accounted for the contradictory findings. For example, the I allele and the risk associated with ACE polymorphism are almost twice as high in Japanese than in whites.31,119
Antioxidants inhibit monocyte adhesion, protect against cytotoxic effects of oxidized LDL, inhibit platelet activation, preserve endothelium-derived nitric oxide activity, and contribute to the production of LDL that is resistant to oxidation. These effects may stabilize the plaque, maintain the vasomotor function, and inhibit platelet activation. Randomized trials and prospective observational studies121-123 indicate that vitamin E and vitamin C levels predict cardiovascular events. New findings document the health effects of antioxidant agents. In the Cambridge Heart Antioxidant Study, 2002 patients with coronary heart disease were randomized to receive 400 to 800 IU of vitamin E per day or placebo and followed up for a median of 1.4 years.121 In the active treatment group the combined end point of cardiovascular death or nonfatal myocardial infarction was significantly reduced (relative risk, 0.53; 95% confidence interval, 0.34-0.83). These favorable findings were not confirmed in a trial conducted in Finland in 1862 men who had a previous myocardial infarction and were smokers. The participants were randomized to 50 mg/d of vitamin E, 20 mg/d of beta carotene, both vitamins, or placebo.124 There were no significant differences in the risk of coronary events between the 4 groups. Use of low doses or different sources of vitamin E (synthetic vs natural) might have accounted for the differences in results between this study and the Cambridge Heart Antioxidant Study. The benefits of vitamin E are not limited to pharmacological supplementation. In observational studies,122,125,126 high dietary intake of vitamin E was associated with a significantly decreased risk of coronary heart disease.
The results of supplementation with beta carotene are less favorable. A randomized trial in 22,071 male physicians found no effect of beta carotene supplementation on incidence of cancer and cardiovascular disease after 14 years of follow-up.127 In a trial involving a total of 18,314 smokers, the combination of beta carotene and vitamin A increased the risk of lung cancer (relative risk, 1.28; 95% confidence interval, 1.04-1.57) and all-cause mortality (relative risk, 1.17; 95% confidence interval, 1.03-1.33), and tended to increase the risk of death from cardiovascular disease (relative risk, 1.26; 95% confidence interval, 0.99-1.61). A recent cohort study128 in Finnish men younger than 60 years has shown that vitamin C deficiency, as assessed by low plasma ascorbate concentration, is a risk factor for coronary heart disease. It is not known whether vitamin C supplementation decreases the risk. The findings from trials using antioxidants suggest that vitamin E supplementation seems to provide the greatest benefits. Among the nonantioxidant vitamins, vitamin D levels have been inversely associated with coronary calcifications.129
Markers of oxidative stress
In a prospective study,130 serum 7 β-hydroxycholesterol, a major oxidation product of cholesterol in membranes, lipid hydroperoxides in LDL measured as thiobarbituric acid-reactive substances and oxidation susceptibility of LDL and very low-density lipoprotein were the strongest predictors of a 3-year increase in carotid wall thickness. F2-isoprostanes are prostaglandin isomers formed by peroxidation of arachidonic acid. The 8-epi prostaglandin F2α and isoprostane F2α are F2-isoprostanes produced in human atherosclerotic lesions.131 Foam cells adjacent to the lipid necrotic core of the plaque are markedly positive for 8-epi IPF2α.132 F2-isoprostanes circulate in plasma and are excreted in urine. Measurement of F2-isoprostanes may be a sensitive, specific, and noninvasive method for measuring oxidative stress.131 Frequent nitric oxide synthase polymorphisms (10% among controls and 30% among cases) have been associated with an excess risk of coronary disease.132
Role of race and sex on risk factors for atherosclerotic disease
As these markers are evaluated it will be important to determine their predictive power in various ethnic groups and in women as well as men. There is evidence that the relative contribution of various risk factors may differ according to race and sex. Compared with white Americans, black and Native Americans tend to have a higher risk of stroke and coronary disease, Japanese have higher rates of stroke but lower rates of coronary disease, and Hispanics tend to have lower rates of both conditions.133-141 Such differences in cardiovascular risk are associated with different distributions in the prevalence of established risk factors. For example, Japanese have low serum cholesterol levels, high intake of alcohol, and low intake of fat and animal proteins.133 In a combined analysis from the Atherosclerosis Risk in Communities Study and CHS, for whites, there was a significantly greater impact on atherosclerosis of smoking and HDL cholesterol among older age groups but a smaller impact of diabetes. For black women, the impact of HDL cholesterol decreased among the older age strata.142 In the Atherosclerosis Risk in Communities Study, black women were more obese than white women, diabetes and hypertension were more frequent among blacks than whites, and black men had higher levels of HDL cholesterol compared with white men.143 Similar patterns were found in CHS.144 In CHS after adjustment for known risk factors, compared with whites, blacks had thicker common carotid walls and lower ankle brachial blood pressure index ratios in both sexes, while internal carotid walls were significantly thinner in black women.144 These findings in CHS suggest that the established risk factors do not explain all the ethnic and sex-related differences in cardiovascular disease rates, and that additional information on new risk factors is needed to improve the risk stratification algorithms.
About 300 cardiovascular risk factors have been reported in the literature. Those described herein address diverse pathogenic mechanisms (Figure 1 and Table 1), and are particularly promising for identifying the most parsimonious combination of markers to accurately predict cardiovascular events in individual age, sex, and ethnic origin groups. Although many of these risk factors have been evaluated in epidemiological studies, most of them are not at present approved for patient screening and there are no uniform reference data for normal values of these measures in the population.
It is expected that the assessment of these new biomarkers will help to identify specific mechanistic patterns that lead to cardiovascular events and will be useful for better targeting preventive interventions. For example, an individual with elevated homocysteine levels will mostly benefit from vitamin B12 and folate supplementation, while a person with increased endothelin levels will benefit from pharmacological interventions that decrease endothelin or antagonize the endothelin receptor. At present, only limited prospective data are available for these new risk factors, and it is unclear which of these new risk factors may have the greatest predictive potential for cardiovascular events. New studies are ongoing or being planned to address this question.
Accepted for publication June 10, 1998.
Corresponding author: Marco Pahor, MD, Department of Preventive Medicine, University of Tennessee, 66 N Pauline, Suite 633, Memphis, TN 38105 (e-mail: mpahor@utmem1.utmem.edu).
1.1997 Joint National Committee, The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
Arch Intern Med. 1997;1572413- 2446
Google ScholarCrossref 2.Burke
APFarb
AMalcom
GTLiang
YHSmialek
JVirmani
R Coronary risk factors and plaque morphology in men with coronary disease who died suddenly.
N Engl J Med. 1997;3361276- 1282
Google ScholarCrossref 3.Stein
JHRosenson
RS Lipoprotein Lp(a) excess and coronary heart disease.
Arch Intern Med. 1997;1571170- 1176
Google ScholarCrossref 4.Bostom
AGCupples
LAJenner
JL
et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger: a prospective study.
JAMA. 1996;276544- 548
Google ScholarCrossref 5.Bostom
AGGagnon
DRCupples
LA
et al. A prospective investigation of elevated lipoprotein(a) detected by electrophoresis and cardiovascular disease in women: The Framingham Heart Study.
Circulation. 1994;901688- 1695
Google ScholarCrossref 6.Nguyen
TTEllefson
RDHodge
DOBailey
KRKottke
TEAbu-Lebdeh
HS Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women.
Circulation. 1997;961390- 1397
Google ScholarCrossref 7.Brown
SAMorrisett
JDBoerwinkle
EHutchinson
RPatsch
W The relation of lipoprotein[a] concentrations and apolipoprotein[a] phenotypes with asymptomatic atherosclerosis in subjects of the Atherosclerosis Risk in Communities (ARIC) Study.
Arterioscler Thromb. 1993;131558- 1566
Google ScholarCrossref 8.Schreiner
PJChambless
LEBrown
SAWatson
RLToole
JHeiss
G Lipoprotein(a) as a correlate of stroke and transient ischemic attack prevalence in a biracial cohort: the ARIC Study—Atherosclerosis Risk in Communities.
Ann Epidemiol. 1994;4351- 359
Google ScholarCrossref 9.Schreiner
PJHeiss
GTyroler
HAMorrisett
JDDavis
CESmith
R Race and gender differences in the association of Lp(a) with carotid artery wall thickness: the Atherosclerosis Risk in Communities (ARIC) Study.
Arterioscler Thromb Vasc Biol. 1996;16471- 478
Google ScholarCrossref 10.Sandholzer
CHallman
DMSaha
N
et al. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups.
Hum Genet. 1991;86607- 614
Google ScholarCrossref 11.Groenemeijer
BEHallman
MDReymer
PW
et al. Genetic variant showing a positive interaction with beta-blocking agents with a beneficial influence on lipoprotein lipase activity, HDL cholesterol, and triglyceride levels in coronary artery disease patients: the Ser447-stop substitution in the lipoprotein lipase gene—REGRESS Study Group.
Circulation. 1997;952628- 2635
Google ScholarCrossref 12.Zhong
SSharp
DSGrove
JS
et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels.
J Clin Invest. 1996;972917- 2923
Google ScholarCrossref 13.Cohen
JCWang
ZGrundy
SMStoesz
MRGuerra
R Variation at the hepatic lipase and apolipoprotein AI/CIII/AIV loci is a major cause of genetically determined variation in plasma HDL cholesterol levels.
J Clin Invest. 1994;942377- 2384
Google ScholarCrossref 14.Chen
LPatsch
WBoerwinkle
E
Hin dIII DNA polymorphism in the lipoprotein lipase gene and plasma lipid phenotypes and carotid artery atherosclerosis.
Hum Genet. 1996;98551- 556
Google ScholarCrossref 15.Kuivenhoven
JAJukema
JWZwinderman
AH
et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis.
N Engl J Med. 1998;33886- 93
Google ScholarCrossref 16.Hirano
KYamashita
SNakajima
N
et al. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan: marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity.
Arterioscler Thromb Vasc Biol. 1997;171053- 1059
Google ScholarCrossref 17.Arai
TYamashita
SSakai
N
et al. A novel nonsense mutation (G181X) in the human cholesteryl ester transfer protein gene in Japanese hyperalphalipoproteinemic subjects.
J Lipid Res. 1996;372145- 2154
Google Scholar 18.Hill
SANazir
DJJayaratne
PBamford
KSMcQueen
MJ Mutations in cholesteryl ester transfer protein and hepatic lipase in a North American population.
Clin Biochem. 1997;30413- 418
Google ScholarCrossref 19.Bagdade
JDKelley
DEHenry
RREckel
RHRitter
MC Effects of multiple daily insulin injections and intraperitoneal insulin therapy on cholesteryl ester transfer and lipoprotein lipase activities in NIDDM.
Diabetes. 1997;46414- 420
Google ScholarCrossref 20.Gudnason
VThormar
KHumphries
SE Interaction of the cholesteryl ester transfer protein I405V polymorphism with alcohol consumption in smoking and non-smoking healthy men, and the effect on plasma HDL cholesterol and apoAI concentration.
Clin Genet. 1997;5115- 21
Google ScholarCrossref 21.Ettinger
WH
JrVerdery
RBWahl
PWFried
LP High density lipoprotein cholesterol subfractions in older people.
J Gerontol. 1994;49M116- M122
Google ScholarCrossref 22.Foger
BLuef
GRitsch
A
et al. Relationship of high-density lipoprotein subfractions and cholesteryl ester transfer protein in plasma to carotid artery wall thickness.
J Mol Med. 1995;73369- 372
Google ScholarCrossref 23.Rapp
JHLespine
AHamilton
RL
et al. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque.
Arterioscler Thromb. 1994;141767- 1774
Google ScholarCrossref 24.Campos
HGenest
JJ
JrBlijlevens
E
et al. Low density lipoprotein particle size and coronary artery disease.
Arterioscler Thromb. 1992;12187- 195
Google ScholarCrossref 25.Austin
MABreslow
JLHennekens
CHBuring
JEWillett
WCKrauss
RM Low-density lipoprotein subclass patterns and risk of myocardial infarction.
JAMA. 1988;2601917- 1921
Google ScholarCrossref 26.Hodis
HNMack
WJDunn
MLiu
CSelzer
RHKrauss
RM Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness.
Circulation. 1997;952022- 2026
Google ScholarCrossref 27.Phillips
NRWaters
DHavel
RJ Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events.
Circulation. 1993;882762- 2770
Google ScholarCrossref 28.Weintraub
MSGrosskopf
IRassin
T
et al. Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: case control study over three years.
BMJ. 1996;312936- 939
Google ScholarCrossref 29.Gaziano
JMHennekens
CHO'Donnell
CJBreslow
JLBuring
JE Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction.
Circulation. 1997;962520- 2525
Google ScholarCrossref 30.Ma
JFolsom
ARLewis
LEckfeldt
JH Relation of plasma phospholipid and cholesterol ester fatty acid composition to carotid artery intima-media thickness: the Atherosclerosis Risk in Communities (ARIC) Study.
Am J Clin Nutr. 1997;65551- 559
Google Scholar 31.Di Minno
GGrandone
EMargaglione
M Clinical relevance of polymorphic markers of arterial thrombosis.
Thromb Haemost. 1997;78462- 466
Google Scholar 32.Sandholzer
CSaha
NKark
JD
et al. Apo(a) isoforms predict risk for coronary heart disease: a study in six populations.
Arterioscler Thromb. 1992;121214- 1226
Google ScholarCrossref 33.Sechi
LAKronenberg
FDe Carli
S
et al. Association of serum lipoprotein(a) levels and apolipoprotein(a) size polymorphism with target-organ damage in arterial hypertension.
JAMA. 1997;2771689- 1695
Google ScholarCrossref 34.Wilson
PWMyers
RHLarson
MGOrdovas
JMWolf
PASchaefer
EJ Apolipoprotein E alleles, dyslipidemia, and coronary heart disease: The Framingham Offspring Study.
JAMA. 1994;2721666- 1671
Google ScholarCrossref 35.de Andrade
MThandi
IBrown
SGotto
A
JrPatsch
WBoerwinkle
E Relationship of the apolipoprotein E polymorphism with carotid artery atherosclerosis.
Am J Hum Genet. 1995;561379- 1390
Google Scholar 36.Nakajima
KSaito
TTamura
A
et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels.
Clin Chim Acta. 1993;22353- 71
Google ScholarCrossref 37.Shimizu
HMori
MSaito
T An increase of serum remnant-like particles in non-insulin–dependent diabetic patients with microalbuminuria.
Clin Chim Acta. 1993;221191- 196
Google ScholarCrossref 38.Akkus
ISaglam
NICaglayan
OVural
HKalak
SSaglam
M Investigation of erythrocyte membrane lipid peroxidation and antioxidant defense systems of patients with coronary artery disease (CAD) documented by angiography.
Clin Chim Acta. 1996;244173- 180
Google ScholarCrossref 39.Shanmugasundaram
KRSrinivas
KSundaram
P
et al. Lipid peroxidation, antioxidant defences and red-cell membrane changes in relation to coronary risk index and symptomatic coronary heart disease.
J Cardiovasc Risk. 1995;2551- 561
Google ScholarCrossref 40.Romon
MNuttens
MCTheret
N
et al. Comparison between fat intake assessed by a 3-day food record and phospholipid fatty acid composition of red blood cells: results from the Monitoring of Cardiovascular Disease-Lille Study.
Metabolism. 1995;441139- 1145
Google ScholarCrossref 41.Chi
YMota de Freitas
DSikora
MBansal
VK Correlations of Na+-Li+ exchange activity with Na+ and Li+ binding and phospholipid composition in erythrocyte membranes of white hypertensive and normotensive individuals: a nuclear magnetic resonance investigation.
Hypertension. 1996;27456- 464
Google ScholarCrossref 42.Laurenzi
MCirillo
MPanarelli
W
et al. Baseline sodium-lithium countertransport and 6-year incidence of hypertension: The Gubbio Population Study.
Circulation. 1997;95581- 587
Google ScholarCrossref 43.Mayer
ELJacobsen
DWRobinson
K Homocysteine and coronary atherosclerosis.
J Am Coll Cardiol. 1996;27517- 527
Google ScholarCrossref 44.Selhub
JJacques
PFBostom
AG
et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis.
N Engl J Med. 1995;332286- 291
Google ScholarCrossref 45.Graham
IMDaly
LERefsum
HM
et al. Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project.
JAMA. 1997;2771775- 1781
Google ScholarCrossref 46.Schwartz
SMSiscovick
DSMalinow
MR
et al. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene.
Circulation. 1997;96412- 417
Google ScholarCrossref 47.Ridker
PMHennekens
CHSelhub
JMiletich
JPMalinow
MRStampfer
MJ Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism.
Circulation. 1997;951777- 1782
Google ScholarCrossref 48.Nygard
ONordrehaug
JERefsum
HUeland
PMFarstad
MVollset
SE Plasma homocysteine levels and mortality in patients with coronary artery disease.
N Engl J Med. 1997;337230- 236
Google ScholarCrossref 49.Morita
HTaguchi
JKurihara
H
et al. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease.
Circulation. 1997;952032- 2036
Google ScholarCrossref 50.Jacobsen
DWGatautis
VJGreen
R
et al. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate concentrations in healthy subjects.
Clin Chem. 1994;40873- 881
Google Scholar 51.Boushey
CJBeresford
SAOmenn
GSMotulsky
AG A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes.
JAMA. 1995;2741049- 1057
Google ScholarCrossref 52.Huber
PLaurent
MDalmon
J Human beta-fibrinogen gene expression: upstream sequences involved in its tissue specific expression and its dexamethasone and interleukin 6 stimulation.
J Biol Chem. 1990;2655695- 5701
Google Scholar 53.Stein
DHeins
MSchoebel
FC
et al. Activation of the fibrinolytic system in patients with coronary artery disease and hyperfibrinogenemia.
Thromb Haemost. 1997;77970- 974
Google Scholar 54.Salomaa
VStinson
VKark
JDFolsom
ARDavis
CEWu
KK Association of fibrinolytic parameters with early atherosclerosis: the ARIC Study—Atherosclerosis Risk in Communities Study.
Circulation. 1995;91284- 290
Google ScholarCrossref 55.Juhan Vague
IPyke
SDAlessi
MCJespersen
JHaverkate
FThompson
SG Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris: ECAT Study Group—European Concerted Action on Thrombosis and Disabilities.
Circulation. 1996;942057- 2063
Google ScholarCrossref 56.Held
CHjemdahl
PRehnqvist
N
et al. Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol: results from the Angina Prognosis Study in Stockholm.
Circulation. 1997;952380- 2386
Google ScholarCrossref 57.Ridker
PMHennekens
CHStampfer
MJManson
JEVaughan
DE Prospective study of endogenous tissue plasminogen activator and risk of stroke.
Lancet. 1994;343940- 943
Google ScholarCrossref 58.Ridker
PMVaughan
DEStampfer
MJManson
JEHennekens
CH Endogenous tissue-type plasminogen activator and risk of myocardial infarction.
Lancet. 1993;3411165- 1168
Google ScholarCrossref 59.Folsom
ARWu
KKRosamond
WDSharrett
ARChambless
LE Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study.
Circulation. 1997;961102- 1108
Google ScholarCrossref 60.Ridker
PMHennekens
CHCerskus
AStampfer
MJ Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men.
Circulation. 1994;902236- 2240
Google ScholarCrossref 61.Cushman
MKuller
LHLemaitre
RNPsaty
BMSharrett
ARTracy
RP Plasmin generation and risk of cardiovascular disease in the elderly [abstract].
Circulation. 1997;96(suppl 1)I- 100
Google Scholar 62.Ridker
PMHennekens
CHLindpaintner
KStampfer
MJMiletich
JP Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men.
Circulation. 1997;9559- 62
Google ScholarCrossref 63.van der Bom
JGde Knijff
PHaverkate
F
et al. Tissue plasminogen activator and risk of myocardial infarction: The Rotterdam Study.
Circulation. 1997;952623- 2627
Google ScholarCrossref 64.Ridker
PMVaughan
DEStampfer
MJGlynn
RJHennekens
CH Association of moderate alcohol consumption and plasma concentration of endogenous tissue-type plasminogen activator.
JAMA. 1994;272929- 933
Google ScholarCrossref 65.Vaughan
DERouleau
JLRidker
PMArnold
JMMenapace
FJPfeffer
MA Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction: HEART Study Investigators.
Circulation. 1997;96442- 447
Google ScholarCrossref 66.Shahar
EFolsom
ARSalomaa
VV
et al. Relation of hormone-replacement therapy to measures of plasma fibrinolytic activity: Atherosclerosis Risk in Communities (ARIC) Study Investigators.
Circulation. 1996;931970- 1975
Google ScholarCrossref 67.Ridker
PMVaughan
DEStampfer
MJManson
JEHennekens
CH Endogenous tissue-type plasminogen activator and risk of myocardial infarction.
Lancet. 1993;3411165- 1168
Google ScholarCrossref 68.Morishita
EAsakura
HJokaji
H
et al. Hypercoagulability and high lipoprotein(a) levels in patients with type II diabetes mellitus.
Atherosclerosis. 1996;1207- 14
Google ScholarCrossref 69.Testa
RBonfigli
ARPiantanelli
LManfrini
STesta
IGregorio
F Relationship between plasminogen activator inhibitor type-1 plasma levels and the lipoprotein(a) concentrations in non-insulin–dependent diabetes mellitus.
Diabetes Res Clin Pract. 1996;33111- 118
Google ScholarCrossref 70.Vaughan
DELazos
SATong
K Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: a potential link between the renin-angiotensin system and thrombosis.
J Clin Invest. 1995;95995- 1001
Google ScholarCrossref 71.van Leeuwen
RTKol
AAndreotti
FKluft
CMaseri
ASperti
G Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells.
Circulation. 1994;90362- 368
Google ScholarCrossref 72.Peiretti
FAlessi
MCHenry
MAnfosso
FJuhan-Vague
INalbone
G Intracellular calcium mobilization suppresses the TNF-alpha-stimulated synthesis of PAI-1 in human endothelial cells: indications that calcium acts at a translational level.
Arterioscler Thromb Vasc Biol. 1997;171550- 1560
Google ScholarCrossref 73.Jansson
JHBoman
KNilsson
TK Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction.
Eur J Clin Pharmacol. 1993;44485- 488
Google ScholarCrossref 74.Zehetgruber
MBeckmann
RGabriel
HChrist
GBinder
BRHuber
K The ACE-inhibitor lisinopril affects plasma insulin levels but not fibrinolytic parameters.
Thromb Res. 1996;83143- 152
Google ScholarCrossref 75.Moriyama
YOgawa
HOshima
S
et al. Captopril reduced plasminogen activator inhibitor activity in patients with acute myocardial infarction.
Jpn Circ J. 1997;61308- 314
Google ScholarCrossref 76.Tracy
RPBovill
EGYanez
D
et al. Fibrinogen and factor VIII, but not factor VII, are associated with measures of subclinical cardiovascular disease in the elderly: results from The Cardiovascular Health Study.
Arterioscler Thromb Vasc Biol. 1995;151269- 1279
Google ScholarCrossref 77.de Maat
MPGreen
Fde Knijff
PJespersen
JKluft
C Factor VII polymorphisms in populations with different risks of cardiovascular disease.
Arterioscler Thromb Vasc Biol. 1997;171918- 1923
Google ScholarCrossref 78.Iacoviello
LDi Castelnuovo
Ade Knijff
P
et al. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction.
N Engl J Med. 1998;33879- 85
Google ScholarCrossref 79.Ghaddar
HBCortes
JSalomaa
V
et al. Correlation of specific platelet activation markers with carotid arterial wall thickness.
Thromb Haemost. 1995;74943- 948
Google Scholar 80.Merlini
PABauer
KAOltrona
L
et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction.
Circulation. 1994;9061- 68
Google ScholarCrossref 81.Cushman
MPsaty
BMMacy
E
et al. Correlates of thrombin markers in an elderly cohort free of clinical cardiovascular disease.
Arterioscler Thromb Vasc Biol. 1996;161163- 1169
Google ScholarCrossref 82.Rosendaal
FRSiscovick
DSSchwartz
SM
et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women.
Blood. 1997;892817- 2821
Google Scholar 83.Tracy
RPPsaty
BMTang
Z
et al. Coagulation factor V genetic polymorphisms associated with cardiovascular disease in the elderly [abstract].
Circulation. 1997;96(suppl 1)I-100- I-101
Google Scholar 84.Ridker
PMCushman
MStampfer
MJTracy
RPHennekens
CH Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
N Engl J Med. 1997;336973- 979
Google ScholarCrossref 85.Thompson
SGKienast
JPyke
SDHaverkate
Fvan de Loo
JC Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.
N Engl J Med. 1995;332635- 641
Google ScholarCrossref 86.Liuzzo
GBiasucci
LMGallimore
JR
et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina.
N Engl J Med. 1994;331417- 424
Google ScholarCrossref 87.Tracy
RPLemaitre
RNPsaty
BM
et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project.
Arterioscler Thromb Vasc Biol. 1997;171121- 1127
Google ScholarCrossref 88.Fukumoto
YShimokawa
HIto
A
et al. Inflammatory cytokines cause coronary arteriosclerosis-like changes and alterations in the smooth-muscle phenotypes in pigs.
J Cardiovasc Pharmacol. 1997;29222- 231
Google ScholarCrossref 89.Torre Amione
GKapadia
SBenedict
COral
HYoung
JBMann
DL Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD).
J Am Coll Cardiol. 1996;271201- 1206
Google ScholarCrossref 90.Wang
XLLiu
SXWilcken
DE Circulating transforming growth factor beta 1 and coronary artery disease.
Cardiovasc Res. 1997;34404- 410
Google ScholarCrossref 91.Pfeiffer
AMiddelberg Bisping
KDrewes
CSchatz
H Elevated plasma levels of transforming growth factor-beta 1 in NIDDM.
Diabetes Care. 1996;191113- 1117
Google ScholarCrossref 92.Mendall
MAPatel
PAsante
M
et al. Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease.
Heart. 1997;78273- 277
Google Scholar 93.Papadopoulos
NGGeorganas
KSkoutellas
VKonstantellos
ELyritis
GP Correlation of interleukin-6 serum levels with bone density in postmenopausal women.
Clin Rheumatol. 1997;16162- 165
Google ScholarCrossref 94.Cohen
HJPieper
CFHarris
TRao
KMCurrie
MS The association of plasma IL-6 levels with functional disability in community-dwelling elderly.
J Gerontol A Biol Sci Med Sci. 1997;52M201- 208
Google ScholarCrossref 95.Cambien
FRicard
STroesch
A
et al. Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure: The Etude Cas-Temoin de l'Infarctus du Myocarde (ECTIM) Study.
Hypertension. 1996;28881- 887
Google ScholarCrossref 96.Fernandez-Real
JMGutierrez
CRicart
W
et al. The TNF-alpha gene Nco I polymorphism influences the relationship among insulin resistance, percent body fat, and increased serum leptin levels.
Diabetes. 1997;461468- 1472
Google ScholarCrossref 97.Murray
REMcGuigan
FGrant
SFReid
DMRalston
SH Polymorphisms of the interleukin-6 gene are associated with bone mineral density.
Bone. 1997;2189- 92
Google ScholarCrossref 98.Gupta
SLeatham
EWCarrington
DMendall
MAKaski
JCCamm
AJ Elevated
Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction.
Circulation. 1997;96404- 407
Google ScholarCrossref 99.Patel
PMendall
MACarrington
D
et al. Association of
Helicobacter pylori and
Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors.
BMJ. 1995;311711- 714
Google ScholarCrossref 100.Sorlie
PDAdam
EMelnick
SL
et al. Cytomegalovirus/herpesvirus and carotid atherosclerosis: the ARIC Study.
J Med Virol. 1994;4233- 37
Google ScholarCrossref 101.Zhou
YFLeon
MBWaclawiw
MA
et al. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy.
N Engl J Med. 1996;335624- 630
Google ScholarCrossref 102.Raza Ahmad
AKlassen
GAMurphy
DA
et al. Evidence of type 2 herpes simplex infection in human coronary arteries at the time of coronary artery bypass surgery.
Can J Cardiol. 1995;111025- 1029
Google Scholar 104.Rathbone
BMartin
DStephens
JThompson
JRSamani
NJ
Helicobacter pylori seropositivity in subjects with acute myocardial infarction.
Heart. 1996;76308- 311
Google ScholarCrossref 105.Mendall
MACarrington
DStrachan
D
et al.
Chlamydia pneumoniae: risk factors for seropositivity and association with coronary heart disease.
J Infect. 1995;30121- 128
Google ScholarCrossref 106.Belch
JJShaw
JWKirk
G
et al. The white blood cell adhesion molecule E-selectin predicts restenosis in patients with intermittent claudication undergoing percutaneous transluminal angioplasty.
Circulation. 1997;952027- 2031
Google ScholarCrossref 107.Blann
ADLip
GYBeevers
DGMcCollum
CN Soluble P-selectin in atherosclerosis: a comparison with endothelial cell and platelet markers.
Thromb Haemost. 1997;771077- 1080
Google Scholar 108.Blann
ADAmiral
JMcCollum
CN Prognostic value of increased soluble thrombomodulin and increased soluble E-selectin in ischaemic heart disease.
Eur J Haematol. 1997;59115- 120
Google ScholarCrossref 109.Morisaki
NSaito
ITamura
K
et al. New indices of ischemic heart disease and aging: studies on the serum levels of soluble intercellular adhesion molecule-1 (ICAM-1) and soluble vascular cell adhesion molecule-1 (VCAM-1) in patients with hypercholesterolemia and ischemic heart disease.
Atherosclerosis. 1997;13143- 48
Google ScholarCrossref 110.Hackman
AAbe
YInsull
W
Jr
et al. Levels of soluble cell adhesion molecules in patients with dyslipidemia.
Circulation. 1996;931334- 1338
Google ScholarCrossref 111.Hwang
SBallantyne
CMSharrett
AR
et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk in Communities (ARIC) Study.
Circulation. 1997;964219- 4225
Google ScholarCrossref 112.Ridker
PMHennekens
CHRoitman-Johnson
BStampfer
MJAllen
J Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men.
Lancet. 1998;35188- 92
Google ScholarCrossref 113.Wenzel
KErnst
MRohde
KBaumann
GSpeer
A DNA polymorphisms in adhesion molecule genes: a new risk factor for early atherosclerosis.
Hum Genet. 1996;9715- 20
Google ScholarCrossref 114.Wenzel
KBlackburn
AErnst
M
et al. Relationship of polymorphisms in the renin-angiotensin system and in E-selectin of patients with early severe coronary heart disease.
J Mol Med. 1997;7557- 61
Google ScholarCrossref 115.Salomone
OAElliott
PMCalvino
RHolt
DKaski
JC Plasma immunoreactive endothelin concentration correlates with severity of coronary artery disease in patients with stable angina pectoris and normal ventricular function.
J Am Coll Cardiol. 1996;2814- 19
Google ScholarCrossref 116.Bennett
MRLittlewood
TDSchwartz
SMWeissberg
PL Increased sensitivity of human vascular smooth muscle cells from atherosclerotic plaques to p53-mediated apoptosis.
Circ Res. 1997;81591- 599
Google ScholarCrossref 117.Bennett
MREvan
GISchwartz
SM Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques.
J Clin Invest. 1995;952266- 2274
Google ScholarCrossref 118.Cai
WDevaux
BSchaper
WSchaper
J The role of Fas/APO 1 and apoptosis in the development of human atherosclerotic lesions.
Atherosclerosis. 1997;131177- 186
Google ScholarCrossref 119.Samani
NJThompson
JRO'Toole
LChanner
KWoods
KL A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction.
Circulation. 1996;94708- 712
Google ScholarCrossref 120.Lindpaintner
KPfeffer
MAKreutz
R
et al. A prospective evaluation of an angiotensin-converting enzyme gene polymorphism and the risk of ischemic heart disease.
N Engl J Med. 1995;332706- 711
Google ScholarCrossref 121.Stephens
NGParsons
ASchofield
PMKelly
FCheeseman
KMitchinson
MJ Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS).
Lancet. 1996;347781- 786
Google ScholarCrossref 122.Kushi
LHFolsom
ARPrineas
RJMink
PJWu
YBostick
RM Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women.
N Engl J Med. 1996;3341156- 1162
Google ScholarCrossref 123.Gale
CRMartyn
CNWinter
PDCooper
C Vitamin C and risk of death from stroke and coronary heart disease in cohort of elderly people.
BMJ. 1995;3101563- 1566
Google ScholarCrossref 124.Rapola
JMVirtamo
JRipatti
S
et al. Randomized trial of α-tocopherol and β-carotene supplements on incidence of major coronary events in men with previous myocardial infarction.
Lancet. 1997;3491715- 1720
Google ScholarCrossref 125.Rimm
EBStampfer
MJAscherio
AGiovannucci
EColditz
GAWillett
WC Vitamin E consumption and the risk of coronary heart disease in men.
N Engl J Med. 1993;3281450- 1456
Google ScholarCrossref 126.Stampfer
MJHennekens
CHManson
JEColditz
GARosner
BWillett
WC Vitamin E consumption and the risk of coronary disease in women.
N Engl J Med. 1993;3281444- 1449
Google ScholarCrossref 127.Hennekens
CHBuring
JEManson
JE
et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease.
N Engl J Med. 1996;3341145- 1149
Google ScholarCrossref 128.Nyyssonen
KParviainen
MTSalonen
RTuomilehto
JSalonen
JT Vitamin C deficiency and risk of myocardial infarction: prospective study of men from eastern Finland.
BMJ. 1997;314634- 638
Google ScholarCrossref 129.Watson
KEAbrolat
MLMalone
LL
et al. Active serum vitamin D levels are inversely correlated with coronary calcification.
Circulation. 1997;961755- 1760
Google ScholarCrossref 130.Salonen
JTNyyssonen
KSalonen
R
et al. Lipoprotein oxidation and progression of carotid atherosclerosis.
Circulation. 1997;95840- 845
Google ScholarCrossref 131.Pratico
DIuliano
LMauriello
A
et al. Localization of distinct F2-isoprostanes in human atherosclerotic lesions.
J Clin Invest. 1997;1002028- 2034
Google ScholarCrossref 132.Hingorani
ADLiang
CFFatibene
J
et al. A common variant of the endothelial nitric oxide synthase gene is a risk factor for coronary atherosclerosis in the East Anglian region of the UK [abstract].
Circulation. 1997;96(suppl 1)I- 545
Google Scholar 133.Reed
DM The paradox of high risk of stroke in populations with low risk of coronary heart disease.
Am J Epidemiol. 1990;131579- 588
Google Scholar 134.Gillum
RF Sudden cardiac death in Hispanic Americans and African Americans.
Am J Public Health. 1997;871461- 1466
Google ScholarCrossref 135.Gillum
RFMussolino
MEMadans
JH Coronary heart disease incidence and survival in African-American women and men: The NHANES I Epidemiologic Follow-up Study.
Ann Intern Med. 1997;127111- 118
Google ScholarCrossref 136.Reeves
MJRemington
PLNashold
RPete
J Chronic disease mortality among Wisconsin Native American Indians, 1984-1993.
Wis Med J. 1997;9627- 32
Google Scholar 139.Wild
SHLaws
AFortmann
SPVarady
ANByrne
CD Mortality from coronary heart disease and stroke for six ethnic groups in California, 1985 to 1990.
Ann Epidemiol. 1995;5432- 439
Google ScholarCrossref 140.Howard
GAnderson
RSorlie
PAndrews
VBacklund
EBurke
GL Ethnic differences in stroke mortality between non-Hispanic whites, Hispanic whites, and blacks: the National Longitudinal Mortality Study.
Stroke. 1994;252120- 2125
Google ScholarCrossref 142.Howard
GManolio
TABurke
GLWolfson
SKO'Leary
DH Does the association of risk factors and atherosclerosis change with age? an analysis of the combined ARIC and CHS cohorts—the Atherosclerosis Risk in Communities (ARIC) and Cardiovascular Health Study (CHS) investigators.
Stroke. 1997;281693- 1701
Google ScholarCrossref 143.Hutchinson
RGWatson
RLDavis
CE
et al. Racial differences in risk factors for atherosclerosis: the ARIC Study—Atherosclerosis Risk in Communities.
Angiology. 1997;48279- 290
Google ScholarCrossref 144.Manolio
TABurke
GLPsaty
BM
et al. Black-white differences in subclinical cardiovascular disease among older adults: the Cardiovascular Health Study—CHS Collaborative Research Group.
J Clin Epidemiol. 1995;481141- 1152
Google ScholarCrossref